A Texas federal judge on Tuesday rejected Becton Dickinson & Co.'s bid to ax a $113.5 million damages verdict in favor of Retractable Technologies Inc. and send the syringe market monopolization case back to a jury for a new trial, ruling that evidence presented during trial supported the jury's findings.
The Delaware Supreme Court on Tuesday ruled a trial court should not have allowed Appriva Medical Inc. shareholders to argue a nonbinding letter of intent affected a merger agreement with ev3 Inc., which was financially backed by Warburg Pincus, reversing a jury’s $250 million judgment against ev3 for breaching the agreement.
Endo International plc said Tuesday that it has reached settlements with several of the remaining plaintiffs suing Endo’s American Medical Systems Inc. subsidiary over allegedly harmful vaginal mesh products, resolving “substantially all” of the claims in the case without admitting any liability or fault.
The U.S. Food and Drug Administration has warned Valeant Pharmaceuticals International Inc. over one of its wrinkle-treatment injection products, involving not its quality or safety but some of the practices of its contract manufacturers, the pharmaceutical firm said Tuesday.
The Ninth Circuit on Tuesday refused to revive a suit accusing California's Alameda County of violating the U.S. Constitution's dormant Commerce Clause with a first-in-the-nation ordinance requiring prescription drug companies to dispose of unwanted prescription drugs, saying the rule doesn't discriminate against interstate commerce.
The U.S. Food and Drug Administration on Monday reported a drop in warning letters related to quality-control violations during medical device production, a bright spot for manufacturers beset in recent years by aggressive enforcement.
California, New York, New Jersey and eight other states on Monday challenged Novartis Pharmaceutical Corp.’s bid for information on their medication adherence programs, saying the information is irrelevant to a whistleblower suit accusing Novartis of paying kickbacks to pharmacies.
Brazilian veterinary products maker Ouro Fino Saúde Animal Participações SA set terms Tuesday for an up to 363.5 million reais ($148 million) initial public offering as the company seeks to tap into the public markets to fuel its domestic expansion, according to the company's preliminary prospectus.
The U.S. Securities and Exchange Commission on Tuesday got tangentially involved in activist investor Bill Ackman’s public feud with Herbalife Ltd., when it accused two people of breaking insider trading rules in the run-up to Pershing Square Management LP’s $1 billion bet against the supplement maker.
A long-awaited Affordable Care Act database revealing money paid to doctors by drug and device makers went live Tuesday, disclosing nearly $3.5 billion spent and potentially reshaping marketing and research efforts by spotlighting questionable financial relationships.
Latham & Watkins LLP cemented its strong start to the week with its second billion-dollar deal in as many days, saying Tuesday that it steered viral disease specialist Alios BioPharma Inc. to its $1.75 billion sale to a Johnson & Johnson drug-development unit.
Tougher standards for inversion deals introduced by the U.S. government last week threaten to upend controversial tax-motivated M&A plays already on the table, but AbbVie Inc. says a historic $54 billion deal to unite it with British drugmaker Shire PLC is still on track despite the crackdown.
As we see more startup activity related to health care information technologies, we will also see a convergence with financial technology companies that will seek to help health care consumers meet their financial needs in a world of higher deductibles and higher out-of-pocket costs, says Jennifer DePalma of O'Melveny & Myers LLP.
A New York federal judge on Monday refused to toss a U.S. Securities and Exchange Commission suit alleging two United Arab Emirates investors reaped $3.7 million through insider trading in Onyx Pharmaceuticals Inc. and Life Technologies Corp., finding it sufficiently states a claim.
The U.S. Supreme Court this term is poised to consider whether to take up yet another hotly debated question related to generic-drug injuries — one that would determine the future of claims that a generics maker failed to update a product's warning label — as well as mull a petition over the scope of the Class Action Fairness Act. Here are some of the most-watched product liability cases.
A Texas federal judge on Monday allowed the plaintiff in a bellwether trial against Johnson & Johnson unit DePuy Orthopaedics Inc. to tell jurors about the 6,500 other cases pending in multidistrict litigation that allege defects in a metal-on-metal hip implant, lifting an earlier order that barred discussion of the other plaintiffs.
Nutritional supplement maker Natrol Inc. on Monday asked a Delaware bankruptcy judge to bless a slate of bid procedures establishing a timetable for a Section 363 sale, including a November auction of the company's assets.
Kahn Swick & Foti LLC attacked Spector Roseman Kodroff & Willis PC on Sunday for its efforts to move a fee dispute between the two firms to federal court, arguing the lawsuit over fees from a securities suit against Abbott Laboratories Inc. belongs in Louisiana state court.
A Minnesota federal judge on Monday refused to throw out the bulk of a securities class action alleging Medtronic Inc. downplayed problems with its bone graft products, saying the investors’ allegations that the medical device maker manipulated studies to drive up its stock price are adequate.
AstraZeneca PLC and two generic drugmakers on Monday pushed a Massachusetts federal court to block two pharmaceutical industry experts from testifying at an upcoming pay-for-delay antitrust class action trial over heartburn drug Nexium, accusing the plaintiffs of trying to rehash discredited arguments.
The Eleventh Circuit found in Finnerty v. Stiefel Laboratories Inc. that a duty to disclose can, in fact, exist with respect to merger discussions. It is, however, not yet clear the extent to which Finnerty has altered the merger landscape, say attorneys with Orrick Herrington & Sutcliffe LLP.
This week, as the Judicial Panel on Multidistrict Litigation embarks on a rare October hearing, we cannot resist mentioning an intriguing MDL petition that involves local rules governing attorney admission and several lawsuits naming members of the federal judiciary — including a JPML member who is also a D.C. district court judge, says Alan Rothman of Kaye Scholer LLP.
In Prevor v. Food and Drug Administration, the D.C. District Court held against the FDA's interpretation of the definition of a medical device included in the Federal Food, Drug and Cosmetic Act. Going on now for five years, the case raises the question — is it time for Congress to act? says Suzanne O'Shea of Faegre Baker Daniels LLP.
In Eli Lilly and Company v. Human Genome Sciences Inc., the English Patents Court recently gave its interpretation of the EU Court of Justice’s most recent decision on supplementary protection certificates. In doing so, the court confirmed that SPCs are available based on patents with claims that define the product in functional terms only, say Andrew Sharples and Emma Muncey of EIP.
New York health practitioners will be required to issue all prescriptions — including prescriptions for controlled substances — in electronic format by 2015, and it is unclear under what circumstances the New York State Department of Health will grant a waiver, say Laurie Cohen and Brooke Lane of Nixon Peabody LLP.
Despite the clear interest in social media engagement by two of its key stakeholders — patients and physicians — the pharma industry has been relatively slow on the uptake. Chief among the concerns is inadvertently violating U.S. Food and Drug Administration regulations that are in place to guard patient welfare, says Sharon Roberg-Perez of Robins Kaplan Miller & Ciresi LLP.
Given the prevalence of corporate integrity agreements in the drug and medical device space, Public Citizen v. U.S. Department of Health and Human Services is a victory for industry — companies subject to such agreements will rely on this case when faced with plaintiffs seeking sensitive information with the Freedom of Information Act, says James Beck of Reed Smith LLP.
Like "big data" and other effective software marketing buzzwords, “cloud” makes something that is very complex sound simple — and even friendly. Most attorneys are not prepared to dig into the distinctions between public, private and hybrid cloud models, or the niceties of how or where their data is transmitted and stored, says David Houlihan of Blue Hill Research Inc.
Despite lingering questions over recent changes in the European medical device regulatory framework, one thing is certain — manufacturers of Class I sterile or measuring, Class II, Class IIb or Class III CE-marked medical devices can expect to be audited by a notified body soon, say Neelam Gill and Jennifer Mountcastle of Thompson Hine LLP.
While the U.S. Food and Drug Administration's Purple Book has been colloquially referred to as an “Orange Book equivalent,” the two contain distinct types of information — their differences reflect the unique nature of biologics and the 351(k) approval process, say attorneys at K&L Gates LLP.